Granted Patent
B2
US 12,590,138 · App. 18/474,781 · Granted Mar 31, 2026
Treatments administering chimeric IgG Fc receptor comprising an extracellular domain of CD64
Inventors:
Jianming Wu (Plymouth, MN); Bruce Kenneth Walcheck (Lino Lakes, MN); Robert Harrison Hullsiek (Minneapolis, MN); Yungfang Li (Minneapolis, MN); Hemant Kumar Mishra (Minneapolis, MN)
Assignee:
Regents of the University of Minnesota
C07K14/70535A61K40/11A61K40/15A61K40/31A61K40/33A61K40/42A61K40/421A61K40/4224C07K16/30C12N5/0636C12N5/0646A61K2239/17A61K2239/21C07K2317/24C07K2319/00C07K2319/03C07K2319/74
View Patent ↗
Loading inventors, assignments & file history…
Abstract
A recombinant immune cell expresses a heterologous IgG Fc receptor. In some embodiments, the heterologous IgG Fc receptor can be a chimeric IgG Fc receptor. Generally, the chimeric IgG Fc receptor includes an extracellular domain, a transmembrane domain, and an intracellular domain. The extracellular domain generally includes a sufficient portion of CD64 to bind to an IgG Fc region. The intracellular domain of the chimeric IgG Fc receptor includes a sufficient portion of an Fc receptor allowing immunoreceptor tyrosine-based activation motif (ITAM) to initiate cell signaling when an IgG Fc region binds to the extracellular domain.
Claims (14)
1 . A method of treating a subject having a tumor, wherein said method comprises: administering, to said subject, recombinant immune cells preloaded with an IgG antibody that specifically binds to cells of said tumor,
wherein said recombinant immune cells comprise a chimeric IgG Fc receptor comprising:
(i) an extracellular domain comprising a CD64 extracellular domain that binds to an IgG Fc region of said IgG antibody;
(ii) a transmembrane domain; and
(iii) an intracellular domain of CD16A comprising an Fc receptor immunoreceptor tyrosine-based activation motif (ITAM), and
wherein said recombinant immune cells kill cells of said tumor within said subject.
2 . The method of claim 1 , wherein said subject is a human.
3 . The method of claim 1 , wherein said CD64 extracellular domain and said intracellular domain of CD16A are derived from a canine species.
4 . The method of claim 1 , wherein said recombinant immune cells are NK cells.
5 . The method of claim 4 , wherein said NK cells are NK cells derived from induced pluripotent stem cells.
6 . The method of claim 1 , wherein said recombinant immune cells are T cells.
7 . The method of claim 6 , wherein said T cells are T cells derived from induced pluripotent stem cells.
8 . The method of claim 1 , wherein said intracellular domain comprises a signaling domain.
9 . The method of claim 8 , wherein the signaling domain comprises a signaling domain of CD27, CD28, CD134 (OX40), CD137 (4-1 BB), FcεR1, NKG2D, CD244 (2B4), FcRγ, DAP10, DAP12, or CD35.
Assignments (2)
CORRECTIVE ASSIGNMENT TO CORRECT THE THE SECOND AND THIRD ASSIGNOR'S NAME PREVIOUSLY RECORDED AT REEL: 67519 FRAME: 130. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT.
Recorded Oct 2, 2024
From: WU, JIANMING; WALCHECK, BRUCE KENNETH; HULLSIEK, ROBERT HARRISON; LI, YUNFANG; MISHRA, HEMANT KUMAR
To: REGENTS OF THE UNIVERSITY OF MINNESOTA
Reel/Frame 069092/0787 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded May 24, 2024
From: WU, JIANMING; WALCHECK, BRUCE; HULLSIEK, ROBERT; LI, YUNFANG; MISHRA, HEMANT KUMAR
To: REGENTS OF THE UNIVERSITY OF MINNESOTA
Reel/Frame 067519/0130 →
Continuity (3)
Division
16758142
Provisional Application
62577425
· Oct 26, 2017
References Cited (276)
US 7618817B2
· Cambell
· 2009
[cited by applicant]
US 20080003225A1
· Vie et al.
· 2008
[cited by applicant]
US 20090196870A1
· Ledbetter et al.
· 2009
[cited by applicant]
US 20120070819A1
· Hengel et al.
· 2012
[cited by applicant]
US 20170081411A1
· Engels et al.
· 2017
[cited by applicant]
US 20200283501A1
· Wu et al.
· 2020
[cited by applicant]
CN 104136458
· 2014
[cited by applicant]
CN 105601746
· 2016
[cited by applicant]
CN 106459918
· 2017
[cited by applicant]
CN 106715467
· 2017
[cited by applicant]
EP 1734119
· 2006
[cited by applicant]
JP H11511649
· 1999
[cited by applicant]
JP 2007528194
· 2007
[cited by applicant]
JP 2008005722
· 2008
[cited by applicant]
JP 2017503510
· 2017
[cited by applicant]
WO WO1996034953
· 1996
[cited by applicant]
WO WO2005017148
· 2005
[cited by applicant]
WO WO2005044996
· 2005
[cited by applicant]
WO WO2006023148
· 2006
[cited by applicant]
WO WO2010040091
· 2010
[cited by applicant]
WO WO2010105817
· 2010
[cited by applicant]
WO WO2013126729
· 2013
[cited by applicant]
WO WO2014145252
· 2014
[cited by applicant]
WO WO2014153270
· 2014
[cited by applicant]
WO WO2014179759
· 2014
[cited by applicant]
WO WO2015148926
· 2015
[cited by applicant]
WO WO2015168613
· 2015
[cited by applicant]
WO WO2015179833
· 2015
[cited by applicant]
WO WO2016040441
· 2016
[cited by applicant]
WO WO2016123333
· 2016
[cited by applicant]
Shim et al. One target, different effects: a comparison of distinct therapeutic antibodies against the same targets. Exp Mol Med 43(10): 539-549, 2011.
[cited by examiner]
Abate-Daga et al., “CAR models: next-generation CAR modifications for enhanced T-cell function,” Mol. Ther.—Oncolytics, 2016, 3:16014, 7 pages.
[cited by applicant]
Ahmed et al., “Human Epidermal Growth Factor Receptor 2 (HER2)-Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma,” J. Clin. Oncol., May 20, 2015, 33(15):1688-1696.
[cited by applicant]
Aker et al., “Extended core sequences from the cHS4 insulator are necessary for protecting retroviral vectors from silencing position effects,” Hum Gene Ther., Apr. 2007, 18(4):333-343.
[cited by applicant]
Alderson et al., “Clinical cancer therapy by NK cells via antibody-dependent cellmediated cytotoxicity,” J Biomed Biotechnol., 2011, 2011:379123, 7 pages.
[cited by applicant]
Altvater et al., “2B4 (CD244) signaling by recombinant antigen-specific chimeric receptors costimulates natural killer cell activation to leukemia and neuroblastoma cell,” Clin. Canc Res., Aug. 1, 2009, 15(15):4857-4866.
[cited by applicant]
Altvater et al., “2B4 (CD244) signaling via chimeric receptors costimulates tumor-antigen specific proliferation and in vitro expansion of human T cells,” Cancer Immunol Immunother., 2009, 58(12):1991-2001.
[cited by applicant]
Anderson et al., “Fcγ receptor type III (CD16) is included in the ζ NK receptor complex expressed by human natural killer cells,” Proc. Natl. Acad. Sci. USA, Mar. 1990, 87(6):2274-2278.
[cited by applicant]
Angelos et al., “Pluripotent stem cell applications for regenerative medicine,” Curr. Opin. Organ Transplant., Dec. 2015, 20(6):663-670.
[cited by applicant]
Argument and Amendment in Response to the First CN Office Action in Chinese Appln. No. 201880084483.4, dated Mar. 16, 2023, 18 pages (with English translation).
[cited by applicant]
Argument and Amendment in Response to the First JP Office Action in Japanese Appln. No. 2020-543244, dated Oct. 5, 2023, 12 pages (with English translation).
[cited by applicant]
Argument and Amendment in Response to the First JP Office Action in Japanese Appln. No. 2022-035778, dated Aug. 14, 2023, 11 pages (with English translation).
[cited by applicant]
Argument and Amendment in Response to the Second CN Office Action in Chinese Appln. No. 201880084483.4, dated Oct. 8, 2023, 22 pages (with English translation).
[cited by applicant]
Argument and Amendment in Response to the Second JP Office Action in Japanese Appln. No. 2022-035778, dated Mar. 1, 2024, 10 pages (with English translation).
[cited by applicant]
Bachanova et al., “Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein,” Blood., 2014, 123(25):3855-3863.
[cited by applicant]
Bachanova., “NK Cells in Therapy of Cancer,” Crit Rev Oncog., 2014, 19(1-2):133-141.
[cited by applicant]
Baghbaderani et al., “cGMP-manufactured human induced pluripotent stem cells are available for pre-clinical and clinical applications,” Stem Cell Reports, Oct. 2015, 5(4):647-659.
[cited by applicant]
Baghbaderani et al., “Manufacturing human induced-pluripotent stem cells for clinical application,” BioProcess International, Oct. 2015, 13(9)s, 8 pages.
[cited by applicant]
Barrett et al., “Chimeric Antigen Receptor Therapy for Cancer,” Annual Rev Med., Jan. 2014, 65:333-347.
[cited by applicant]
Battella et al., “Natural killer (NK) cells and anti-tumor therapeutic mAb: unexplored interactions,” J. Leukoc. Biol., Jan. 2016, 99(1):87-96.
[cited by applicant]
Beatty et al., “Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies,” Canc Immunol Res., Feb. 2014, 2(2):112-120.
[cited by applicant]
Bergeron et al., “Comparative functional characterization of canine IgG subclasses,” Vet. Immunol. Immunopathology, Jan. 15, 2014, 157:31-41.
[cited by applicant]
Bhat et al., “Serial killing of tumor cells by human natural killer cells—enhancement by therapeutic antibodies,” PLoS One, Mar. 2007, 2(3):e326.
[cited by applicant]
Bhattacharya et al. Impact of genetic variation on three dimensional structure and function of proteins. PLoS ONE 12(3): e0171355, 2017.
[cited by applicant]
Binyamin et al., “Blocking NK cell inhibitory self-recognition promotes antibody-dependent cellular cytotoxicity in a model of anti-lymphoma therapy,” J Immunol., May 1, 2008, 180(9):6392-6401.
[cited by applicant]
Bollino et al., “Chimeric antigen receptor-engineered natural killer and natural killer T cells for cancer immunotherapy,” Transl Res., Sep. 2017, 187:32-43.
[cited by applicant]
Bork, P. Go hunting in sequence databases but watch out for the traps. Trends in Genetics 12(10): 425-427, 1996.
[cited by applicant]
Bork, P. Powers and pitfalls in sequence analysis: the 70% hurdle. Genome Res 10: 398-400, 2000.
[cited by applicant]
Brenner. S.E. Errors in genome annotation. Trends in Genetics 15:132-133, 1999.
[cited by applicant]
Bruhns et al., “Specificity and affinity of human Fcγ receptors and their polymorphic variants for human IgG subclasses,” Blood, Apr. 2009, 113(16):3716-3725.
[cited by applicant]
Bryant et al., “Calculation of lytic units for the expression of cell-mediated cytotoxicity,” J Immunol Methods., 1992, 146(1):91-103.
[cited by applicant]
Bryceson et al., “Activation, coactivation, and costimulation of resting human natural killer cells,” Immunol Rev., Dec. 2006, 214(1):73-91.
[cited by applicant]
Bryceson et al., “Molecular mechanisms of natural killer cell activation,” J Innate Immun., 2011, 3:216-226.
[cited by applicant]
Bryceson et al., “Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion,” Blood., Jan. 2006, 107(1):159-166.
[cited by applicant]
Burgess-Beusse et al., “The insulation of genes from external enhancers and silencing chromatin,” PNAS., Dec. 10, 2002, 99(suppl 4):16433-16437.
[cited by applicant]
Caescu et al., “Active-site determinants of substrate recognition by the metalloproteinases TACE and ADAMI O,” Biochem J., Oct. 2009, 424(1):79-88.
[cited by applicant]
Caligiuri., “Human natural killer cells,” Blood., Aug. 1, 2008, 112(3):461-469.
[cited by applicant]
Carlsten et al., “Genetic manipulation of NK cells for cancer immunotherapy: techniques and clinical implications,” Front Immunol., Jun. 10, 2015, 6(Article 266), 9 pages.
[cited by applicant]
Carotta, “Targeting NK Cells for Anticancer Immunotherapy: Clinical and Preclinical Approaches,” Front. Immunol., Apr. 2016, 7:152.
[cited by applicant]
Chae et al. Qualitatively differential regulation of T cell activation and apoptosis by T cell receptor zeta chain ITAMs and their tyrosine residues. Int Immunol 16(9): 1225-1236, 2004.
[cited by applicant]
Chang et al., “A Chimeric Receptor with NKG2D Specificity Enhances Natural Killer Cell Activation and Killing of Tumor Cells,” Cancer Res., Mar. 15, 2013, 73(6):1777-1786.
[cited by applicant]
Chen et al., “Gene-modified NK-92MI cells expressing a chimeric CD16-BB-ζ or CD64-BB-ζ receptor exhibit enhanced cancer-killing ability in combination with therapeutic antibody,” Oncotarget, Mar. 15, 2017, 8(23):37128-3…
[cited by applicant]
Cheng et al., “NK cell-based immunotherapy for malignant diseases,” Cell Mol. Immunol., 2013, 10:230-252.
[cited by applicant]
Childs et al., “Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens,” Nat. Rev. Drug Disc., 2015, 14:487-498.
[cited by applicant]
Choi et al., “Hematopoietic and endothelial differentiation of human induced pluripotent stem cells,” Stem Cells, 2009, 27:559-567.
[cited by applicant]
Chowdhury et al., “Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity,” PNAS, Jan.…
[cited by applicant]
CN Decision of Rejection in Chinese Appln. No. 201880084483.4, dated Nov. 10, 2023, 17 pages (with English translation).
[cited by applicant]
CN Office Action in Chinese Appln. No. 201880084483.4, dated Jul. 14, 2023, 17 pages (with English translation).
[cited by applicant]
CN Office Action in Chinese Appln. No. 201880084483.4, dated Nov. 2, 2022, 11 pages (with English translation).
[cited by applicant]
Coenon et al. From CD16a biology to antibody-dependent cell-mediated cytotoxicity improvement. Front Immunol 13: 913215, 2022.
[cited by applicant]
Cox et al., “Tumor-associated and immunochemotherapy-dependent long-term alterations of the peripheral blood NK cell compartment in DLBCL patients,” Oncoimmunology, Jan. 2015, 4(3):e990773.
[cited by applicant]
Coxon et al., “Fcγ RIII mediates neutrophil recruitment to immune complexes, a mechanism for neutrophil accumulation in immune-mediated inflammation,” Immunity, Jun. 2001, 14(6):693-704.
[cited by applicant]
Deguine et al., “Cutting edge: tumor-targeting antibodies enhance NKG2D-mediated NK cell cytotoxicity by stabilizing NK cell-tumor cell interactions,” J Immunol., Dec. 2012, 189(11):5493-5497.
[cited by applicant]
Denman et al., “Membrane-Bound IL-21 Promotes Sustained Ex Vivo Proliferation of Human Natural Killer Cells,” Plos One, Jan. 2012, 7(1):e30264, 13 pages.
[cited by applicant]
Dhar et al., “NKG2D and its ligands in cancer,” Curr. Opinion Immunol., Apr. 2018, 51:55-61.
[cited by applicant]
Dietrich et al., “Identification of the kinesin KifC3 as a new player for positioning of peroxisomes and other organelles in mammalian cells,” Biochimica et Biophysica Acta (BBA)-Molecular Cell Research, Dec. 2013, 1833…
[cited by applicant]
Doedens et al., “Stimulation-induced down-regulation of tumor necrosis factor-alpha converting enzyme,” J Biol Chem., 2000, 275:14598-14607.
[cited by applicant]
Doerks et al. Protein annotation: detective work for function prediction. Trends in Genetics 14:248-250, 1998.
[cited by applicant]
Dolstra et al., “Successful Transfer of Umbilical Cord Blood CD34+ Hematopoietic Stem and Progenitor-derived NK Cells in Older Acute Myeloid Leukemia Patients,” Clin Cancer Res., Aug. 2017, 23(15):4107-4118.
[cited by applicant]
Dong et al., “Fcγ receptor Illa single-nucleotide polymorphisms and haplotypes affect human IgG binding and are associated with lupus nephritis in African Americans,” Arthritis Rheumatol., May 2014, 66(5):1291-1299.
[cited by applicant]
Dotti et al., “Design and development of therapies using chimeric antigen receptor- expressing T cells,” Immunol. Review, Jan. 2014, 257(1):107-126.
[cited by applicant]
Eagle et al.., “Promiscuity and the single receptor: NKG2D,” Nat Rev Immunol., 2007, 7:737-744.
[cited by applicant]
Eguizabal et al., “Natural killer cells for cancer immunotherapy: pluripotent stem cells-derived NK cells as an immunotherapeutic perspective,” Front Immunol., 2014, 5:439, 10 pages.
[cited by applicant]
Ellsworth et al. Generation of a high-affinity Fcgamma receptor by Ig-domain swapping between human CD64A and CD16A. Protein Eng Design Selection 23(4): 299-309, 2010.
[cited by applicant]
Feehan et al., “Shedding of the lymphocyte L-selectin adhesion molecule is inhibited by a hydroxamic acid-based protease inhibitor. Identification with an L-selectinalkaline phosphatase reporter,” J Biol Chem., 1996, 27…
[cited by applicant]
Fenton et al. Rheostat positions: a new classification of protein positions relevant to pharmacogenomics. Medicinal Chem Res 29:1133-1146,2020.
[cited by applicant]
Fesnak et al., “Engineered T cells: the promise and challenges of cancer immunotherapy,” Nat Rev Canc., 2016, 16:566-581.
[cited by applicant]
Figueroa et al., “Chimeric Antigen Receptor Engineering: A Right Step in the Evolution of Adoptive Cellular Immunotherapy,” Int Rev Immunol., 2015, 34(2):154-187.
[cited by applicant]
Galon et al., “Identification of the cleavage site involved in production of plasma soluble Fcγ receptor type III (CD16),” Eur J Immunol., 1998, 28:2101-2107.
[cited by applicant]
Garrity et al., “The activating NKG2D receptor assembles in the membrane with two signaling dimers into a hexameric structure,” PNAS, May 24, 2005, 102(21):7641-7646.
[cited by applicant]
Geller et al., “A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer,” Cytotherapy, Jan. 2011, 13(1):98-107.
[cited by applicant]
Geller et al., “Intraperitoneal delivery of human natural killer cells for treatment of ovarian cancer in a mouse xenograft model,” Cytotherapy, 2013, 15:1297-1306.
[cited by applicant]
Geller et al., “Use of allogeneic NK cells for cancer immunotherapy,” Immuno Ther., Decmber 2011, 3(12):1445-1459.
[cited by applicant]
Giudice et al., “Genetic Modification of Human Embryonic Stem Cells for Derivation of Target Cells,” Cell Stem Cell, May 8, 2008, 2(5):422-433.
[cited by applicant]
Gong et al., “Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells,” Leukemia., 1994, 8:652-658.
[cited by applicant]
Granzin et al., “Fully automated expansion and activation of clinical-grade natural killer cells for adoptive immunotherapy,” Cytotherapy, May 2015, 17(5):621-632.
[cited by applicant]
Grupp et al., “Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia,” N. Engl. J. Med., Apr. 18, 2013, 368:1509-1518.
[cited by applicant]
Guillerey et al., “Targeting natural killer cells in cancer immunotherapy,” Nat Immunol., 2016, 17:1025-1036.
[cited by applicant]
Guo et al. Protein tolerance to random amino acid change. Proc Natl Acad Sci USA 101(25): 9205-9210, 2004.
[cited by applicant]
Handgretinger et al., “Exploitation of natural killer cells for the treatment of acute leukemia,” Blood, Jun. 30, 2016, 127:3341-3349.
[cited by applicant]
Harrison et al., “High affinity IgG binding by FcγRI (CD64) is modulated by two distinct IgSF domains and the transmembrane domain of the receptor,” Protein Eng., Mar. 1998, 11(3):225-232.
[cited by applicant]
Harrison et al., “Involvement of a metalloprotease in spontaneous and phorbol ester-induced release of natural killer cell-associated Fcγ RIii (CD 16-11),” J Immunol., Nov. 15, 1991, 147(10):3459-3465.
[cited by applicant]
Hassan et al., “Mesothelin targeted cancer immunotherapy,” Euro. J. Canc., Jan. 2008, 44(1):46-53.
[cited by applicant]
Hellstrom et al., “Overexpression of HER-2 in ovarian carcinomas,” Cancer Res., 2001, 61:2420-2423.
[cited by applicant]
Hermanson et al., “Induced Pluripotent Stem Cell-Derived Natural Killer Cells for Treatment of Ovarian Cancer,” Stem Cells, Jan. 2016, 34(1):93-101.
[cited by applicant]
Hermanson et al., “Utilizing chimeric antigen receptors to direct natural killer cell activity,” Front Immunol, Apr. 2015, 6:195, 6 pages.
[cited by applicant]
Hermanson et al., “Utilizing chimeric antigen receptors to direct natural killer cell activity,” Front. Immunol., Apr. 28, 2015, 6(Article 195), 6 pages.
[cited by applicant]
Ho et al., “Costimulation of Multiple NK Cell Activation Receptors by NKG2D,” J Immunol., Oct. 1, 2002, 169(7):3667-3675.
[cited by applicant]
Horowitz et al., “Genetic and Environmental Determinants of Human NK Cell Diversity Revealed by Mass Cytometry,” Sci. Transl. Med., Oct. 2013, 5(208):208ra145.
[cited by applicant]
Hou et al., “The Cytoplasmic Tail of FcγRIIIAα Is Involved in Signaling by the Low Affinity Receptor for Immunoglobulin G,” J. Biol. Chemistry, Sep. 13, 1996, 271(37):22815-22822.
[cited by applicant]
Hsu et al., “NK cells converge lytic granules to promote cytotoxicity and prevent bystander killing,” J. Cell. Biol., Dec. 2016, 215(6):875-889.
[cited by applicant]
Huizinga et al., “Soluble Fcγ receptor III in human plasma originates from release by neutrophils,” J Clin Invest., Aug. 1990, 86(2):416-423.
[cited by applicant]
Hulett et al. The second and third extracellular domains of FcyRI (CD64) confer the unique high affinity binding of IgG2a. Mol Immunol 35: 989-996, 1998.
[cited by applicant]
Imai et al., “Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells,” Blood, 2005, 106:376-383.
[cited by applicant]
Jewett et al., “Tumor induced inactivation of natural killer cell cytotoxic function; implication in growth, expansion and differentiation of cancer stem cells,” J Cancer, 2011, 2:443-457.
[cited by applicant]
Jing et al., “Identification of an ADAM17 Cleavage Region in Human CD16 (FcγRIII) and the Engineering of a Non-Cleavable Version of the Receptor in NK Cells,” PLoS One, Mar. 27, 2015, 10(3):e0121788, 14 pages.
[cited by applicant]
JP Office Action in Japanese Appln. No. 2020-543244, dated Jul. 5, 2023, 18 pages (with English translation).
[cited by applicant]
JP Office Action in Japanese Appln. No. 2022-035778, dated May 15, 2023, 9 pages (with English translation).
[cited by applicant]
JP Office Action in Japanese Appln. No. 2022-035778, dated Oct. 16, 2023, 7 pages (with English translation).
[cited by applicant]
JP Trial and Appeal Decision in Japanese Appln. No. 2020-543244, dated Nov. 27, 2023, 23 pages (with English translation).
[cited by applicant]
Kahn et al., “Membrane proximal cleavage of L-selectin: identification of the cleavage site and a 6-kD transmembrane peptide fragment of L-selectin,” J Cell Biol., 1994, 125:461-470.
[cited by applicant]
Kaufman, “Toward clinical therapies using hematopoietic cells derived from human pluripotent stem cells,” Blood, 2009, 114:3513-3523.
[cited by applicant]
Kirkwood et al., “Immunotherapy of cancer in 2012,” CA Cancer J Clin., 2012, 62:309-335.
[cited by applicant]
Kiyoshi et al., “Structural basis for binding of human IgG1 to its high-affinity human receptor FcγRI,” Nat. Commun., Apr. 2015, 6:6866.
[cited by applicant]
Klingemann et al., “Natural Killer Cells for Immunotherapy—Advantages of the NK-92 Cell Line over Blood NK Cells,” Front Immunol., Mar. 14, 2016, 7(Article 91), 7 pages.
[cited by applicant]
Klingemann, “Are natural killer cells superior CAR drivers?” OncoImmunology, Apr. 2014, 3(4):e28147, 5 pages.
[cited by applicant]
Knorr et al., “Clinical-Scale Derivation of Natural Killer Cells From Human Pluripotent Stem Cells for Cancer Therapy,” Stem Cells Transl. Medicine, Apr. 2013, 2(4):274-283.
[cited by applicant]
Knorr et al., “Clinical-Scale Derivation of Natural Killer Cells From Human Pluripotent Stem Cells for Cancer Therapy,” Stem Cells Transl Med, Apr. 2013, 2(4):274-283.
[cited by applicant]
Knorr et al., “Engineered human embryonic stem cell-derived lymphocytes to study in vivo trafficking and immunotherapy,” Stem Cells and Development, Feb. 19, 2013, 22:1861-1869.
[cited by applicant]
Koch et al., “Activating natural cytotoxicity receptors of natural killer cells in cancer and infection,” Trends in Immunology, Apr. 2013, 34(4):182-91.
[cited by applicant]
Koehl et al., “Advances in clinical NK cell studies: Donor selection, manufacturing and quality control,” OncoImmunology, 2016, 5(4):e1115178, 12 pages.
[cited by applicant]
Koene et al., “FcγRIIIa-158V/F Polymorphism Influences the Binding of IgG by Natural Killer Cell FcγRIIIa, Independently of the FcγRIIIa-48L/R/H Phenotype,” Blood, Aug. 1997, 90(3):1109-1114.
[cited by applicant]
Koneru et al., “IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo,” OncoImmunology, 2015, 4(3):e994446, 12 pages.
[cited by applicant]
Kruse et al., “Natural cytotoxicity receptors and their ligands,” Immunology and Cell Biology, Mar. 2014, 92(3):221-229.
[cited by applicant]
Kwon et al., “Stepwise phosphorylation of p65 promotes NF-κB activation and NK cell responses during target cell recognition,” Nature Comm., 2016, 7:11686, 15 pages.
[cited by applicant]
Lai et al., “Alterations in expression and function of signal-transducing proteins in tumor-associated T and natural killer cells in patients with ovarian carcinoma,” Clin Cancer Res., 1996, 2:161-173.
[cited by applicant]
Lajoie et al., “ADAM17-mediated shedding of FcγRIIIA on human NK cells: identification of the cleavage site and relationship with activation,” J Immunol., 192(2):741-751, Jan. 15, 2014.
[cited by applicant]
Lanier et al., “Co-association of CD3ζ with a receptor (CD16) for IgG Fc on human natural killer cells,” Nature, Dec. 14, 1989, 342:803-805.
[cited by applicant]
Lanier., “Up on the tightrope: natural killer cell activation and inhibition, ” Nature Immunology, 2008, 9:495-502.
[cited by applicant]
Lanitis et al., “Primary human ovarian epithelial cancer cells broadly express HER2 at immunologically-detectable levels,” PLOS ONE, 2012, 7:e49829, 12 pages.
[cited by applicant]
Le Bouteiller et al., “Engagement of CD160 receptor by HLA-C is a triggering mechanism used by circulating natural killer (NK) cells to mediate cytotoxicity,” PNAS, Dec. 24, 2002, 99(26):16963-16968.
[cited by applicant]
Le Garff-Tavernier et al., “Human NK cells display major phenotypic and functional changes over the life span,” Aging Cell., 2010, 9:527-535.
[cited by applicant]
Letourneur et al., “Characterization of the family of dimers associated with Fc receptors (Fc epsilon RI and Fc gamma RIII),” J. Immunol., Oct. 1991, 147(8):2652-2656.
[cited by applicant]
Li et al., “ADAMI17 deficiency by mature neutrophils has differential effects on L-selectin shedding,” Blood, 2006, 108:2275-2279.
[cited by applicant]
Li et al., “Expression of chimeric antigen receptors in natural killer cells with a regulatory-compliant non-viral method,” Cancer Gene Therapy, 2010, 17:147-154.
[cited by applicant]
Li et al., “Human iPSC-derived natural killer cells engineered with chimeric antigen receptors enhance anti-tumor activity,” Cell Stem Cell, 2018, 23:181-192.
[cited by applicant]
Li et al., “The Unique Cytoplasmic Domain of Human FcγRIIIA Regulates Receptor-Mediated Function,” J. Immunology, Nov. 2012, 189(9):4284-4294.
[cited by applicant]
Lin-Moshier et al., “Re-evaluation of the role of calcium homeostasis endoplasmic reticulum protein (CHERP) in cellular calcium signaling,” J. Biol. Chem., 2013, 288:355-367.
[cited by applicant]
Liu et al., “Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity,” Leukemia, 2018, 32:520-531.
[cited by applicant]
Long et al., “ADAM17 activation in circulating neutrophils following bacterial challenge impairs their recruitment,” J. Leukoc. Biol., Sep. 2012, 92(3):667-672.
[cited by applicant]
Long et al., “Controlling Natural Killer Cell Responses: Integration of Signals for Activation and Inhibition,” Annual Rev. Immunol., 2013, 31:227-258.
[cited by applicant]
Long et al., “In vivo role of leukocyte ADAM17 in the inflammatory and host responses during
[cited by applicant]
Long, “Negative signaling by inhibitory receptors: the NK cell paradigm,” Immunol Rev., Aug. 2008, 224(1):70-84.
[cited by applicant]
Louis et al., “Cloning and sequencing of the cellular-viral junctions from the human adenovirus type 5 transformed 293 cell line,” Virology, 1997, 233:423-429.
[cited by applicant]
Love et al., “ITAM-mediated Signaling by the T-Cell Antigen Receptor,” Cold Spring Harb. Perspect. Biol., 2010, 2:a002485, 12 pages.
[cited by applicant]
Lu et al. Structure of FcyRI in complex with Fc reveals the importance of glycan recognition for high-affinity IgG binding. Proc Natl Acad Sci USA: 112(3): 833-838, 2015.
[cited by applicant]
Maccio et al., “Inflammation and ovarian cancer,” Cytokine., 2012, 58:133-147.
[cited by applicant]
Matala et al., “The cytoplasmic domain of L-selectin participates in regulating L-selectin endoproteolysis,” J Immunol., Aug. 1, 2001, 167(3):1617-1623.
[cited by applicant]
Maude et al., “CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia,” Blood, Jun. 25, 2015, 125(26):4017-4023.
[cited by applicant]
Mezyk et al., “Structure and functions of tumor necrosis factor-alpha converting enzyme,” Acta Biochim Pol., 2003, 50:625-645.
[cited by applicant]
Migaki et al., “Mutational analysis of the membrane-proximal cleavage site of L-selectin: relaxed sequence specificity surrounding the cleavage site,” J Exp Med., 1995, 182:549-557.
[cited by applicant]
Miller et al., “Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer,” Blood, 2005, 105(8):3051-3057.
[cited by applicant]
Miller, “Therapeutic applications: natural killer cells in the clinic,” ASH Education Program Book, Dec. 2013, 2013(1):247-53.
[cited by applicant]
Mishra et al., “Anti-ADAM17 monoclonal antibody MEDI3622 increases IFNγ production by human NK cells in the presence of antibody-bound tumor cells,” Cancer Immunol. Immunotherapy, Sep. 2018, 67(9):1407-1416.
[cited by applicant]
Montaldo et al., “Human NK cell receptors/markers: a tool to analyze NK cell development, subsets and function,” Cytometry A., 2013, 83:702-713.
[cited by applicant]
Moriarity et al., “Modular assembly of transposon integratable multigene vectors using RecWay assembly,” Nucleic Acids Res., Apr. 1, 2013, 41(8):e92, 12 pages.
[cited by applicant]
Morvan et al.., “NK cells and cancer: you can teach innate cells new tricks,” Nat Rev Cancer, 2016, 16:7-19.
[cited by applicant]
Nakajima et al., “Activating interactions in human NK cell recognition: the role of 2B4-CD48,” Eur. J. Immunol., May 1999, 29(5):1676-1683.
[cited by applicant]
Nakamura et al., “Presence and primary sequence of a high-affinity IgG receptor on canine mastocytoma (CM-MC) cells,” Immunogenetics, Jun. 17, 2003, 55:271-274.
[cited by applicant]
Ng et al., “A protocol describing the use of a recombinant protein-based, animal product-free medium (APEL) for human embryonic stem cell differentiation as spin embryoid bodies,” Nat Protoc., 2008, 3:768-776.
[cited by applicant]
Ng et al., “Forced aggregation of defined Nos. of human embryonic stem cells into embryoid bodies fosters robust, reproducible hematopoietic differentiation,” Blood, 2005, 106:1601-1603.
[cited by applicant]
Ngo et al. Computational complexity, protein structure prediction, and the Levinthal paradox. in The Protein Folding Problem and Tertiary Structure Prediction, pp. 492-495, 1994.
[cited by applicant]
Ni et al., “Expression of Chimeric Receptor CD4ζ by Natural Killer Cells Derived from Human Pluripotent Stem Cells Improves In Vitro Activity but Does Not Enhance Suppression of HIV Infection In Vivo,” Stem Cells, Apr. …
[cited by applicant]
Ni et al., “Hematopoietic and Nature Killer Cell Development from Human Pluripotent Stem Cells,” Methods Mol. Biol., Embryonic Stem Cell Immunobiology: Methods and Protocols, Jun. 2013, 1029:33-41.
[cited by applicant]
Ni et al., “Human pluripotent stem cells produce natural killer cells that mediate anti-HIV-1 activity by utilizing diverse cellular mechanisms,” J Viral, 2011, 85:43-50.
[cited by applicant]
Nimmerjahn et al., “Fcγ receptors as regulators of immune responses,” Nat. Rev. Immunol., Jan. 2008, 8(1):34-47.
[cited by applicant]
Ory et al., “Sequences of complementary DNAs that encode the NA1 and NA2 forms of Fc receptor III on human neutrophils,” J. Clin. Invest., Nov. 1989, 84(5):1688-1691.
[cited by applicant]
Ott et al., “Potent, exceptionally selective, orally bioavailable inhibitors of TNF-alpha Converting Enzyme (TACE): novel 2-substituted-1H-benzo[d]imidazol-1-yl)methyl)benzamide Pl′ substituents,” Bioorg. Med. Chem. Let…
[cited by applicant]
PCT International Preliminary Report on Patentability in International Appln. No. PCT/US2018/057689, dated Apr. 28, 2020, 5 pages.
[cited by applicant]
PCT International Search Report and Written Opinion in International Appln. No. PCT/US2018/057689, dated Jan. 28, 2019, 8 pages.
[cited by applicant]
Peruzzi et al., “Membrane-type 6 matrix metalloproteinase regulates the activation-induced downmodulation of CD16 in human primary NK cells,” J Immunol., Aug. 15, 2013, 191(4):1883-1894.
[cited by applicant]
Peschon et al., “An essential role for ectodomain shedding in mammalian development,” Science, 1998, 282:1281-1284.
[cited by applicant]
Porter et al., “Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia,” N. Engl. J. Med., 2011, 365:725-733.
[cited by applicant]
Qasim et al., “Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells,” Sci. Transl. Med., Jan. 25, 2017, 9(374):eaaj2013, 9 pages.
[cited by applicant]
Ramos et al., “CAR-T Cell Therapy for Lymphoma,” Annu. Rev. Med., 2016, 67:165-183.
[cited by applicant]
Ran et al., “RUNXla enhances hematopoietic lineage commitment from human embryonic stem cells and inducible pluripotent stem cells,” Blood, 2013, 121:2882-2890.
[cited by applicant]
Ravetch et al., “Alternative membrane forms of Fcγ RIII(CD16) on human natural killer cells and neutrophils. Cell type-specific expression of two genes that differ in single nucleotide substitutions,” J. Exp. Med., Aug.…
[cited by applicant]
Reiss et al., “The “a disintegrin and metalloprotease” (ADAM) family of sheddases: physiological and cellular functions,” Semin. Cell. Dev. Biol., 2009, 20:126-137.
[cited by applicant]
Remington's Pharmaceutical Sciences, 17th ed., Gennaro (ed), Jan. 1, 1985, 1984 pages.
[cited by applicant]
Request for Reexamination in Response to the CN Decision of Rejection in Chinese Appln. No. 201880084483.4, dated Feb. 27, 2024, 23 pages (with English translation).
[cited by applicant]
Romee et al., “Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia,” Sci. Transl. Med., Sep. 21, 2016, 8(357):357ra123, 13 pages.
[cited by applicant]
Romee et al., “NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17),” Blood, May 1, 2013, 121(18):3599-3608.
[cited by applicant]
Rosen et al., “A Structural Basis for the Association of DAP12 with Mouse, but Not Human, NKG2D,” J. Immunol., Aug. 15, 2004, 173(4):2470-2478.
[cited by applicant]
Sadelain et al., “The basic principles of chimeric antigen receptor design,” Cancer Discovery, Apr. 2013, 3(4):388-98.
[cited by applicant]
Sakamoto et al., “Phase I clinical trial of autologous NK cell therapy using novel expansion method in patients with advances digestive cancer,” J. Transl. Med., Aug. 25, 2015, 13:277, 13 pages.
[cited by applicant]
Seidel et al., “Natural killer cell mediated antiboy-dependent cellular cytotoxicity in tumor immunotherapy with therapeutic antibodies,” Front. Immunology, Mar. 27, 2013, 4:76, 9 pages.
[cited by applicant]
Selvaraj et al., “The major Fc receptor in blood has a phosphatidylinositol anchor and is deficient in paroxysmal noctural hemoglobinuria,” Nature, Jun. 9, 1988, 333(6173):565-567.
[cited by applicant]
Sentman et al., “NKG2D CARs as cell therapy for cancer,” Cancer J., Mar./Apr. 2014, 20(2):156-159.
[cited by applicant]
Shemesh et al., “Splice variants of human natural cytotoxicity receptors: novel innate immune checkpoints,” Cancer Immunology, Immunotherapy, Dec. 2017, 67(3), 13 pages.
[cited by applicant]
Shilov et al., “The Paragon Algorithm, a next generation search engine that uses sequence temperature values and feature probabilities to identify peptides from tandem mass spectra,” Mal. Cell Proteomics., Sep. 2007, 6(…
[cited by applicant]
Shimasaki et al., “A clinically adaptable method to enhance the cytotoxicity of natural killer cells against B-cell malignancies,” Cytotherapy, Aug. 1, 2012, 14(7):830-840.
[cited by applicant]
Siegel et al., “Cancer statistics, 2012” CA Cancer J. Clin., 2012, 62:10-29.
[cited by applicant]
Sivori et al., “2B4 functions as a co-receptor in human NK cell activation,” Eur. J. Immunol., 2000, 30(3):787-793.
[cited by applicant]
Skolnick et al. From genes to protein structure and function: novel applications of computational approaches in the genomic era. Trends Biotechnol 18(1):34-39 2000.
[cited by applicant]
Smith et al. The challenges of genome sequence annotation or the devil is in the details. Nature Biotechnol 15: 1222-1223, 1997.
[cited by applicant]
Smyth et al., “Activation of NK cell cytotoxicity,” Mol. Immunol., Feb. 2005, 42(4):501-510.
[cited by applicant]
Snyder et al., “Expression of a Recombinant High Affinity IgG Fc Receptor by Engineered NK Cells as a Docking Platform for Therapeutic mAbs to Target Cancer Cells,” Front. Immunology, Dec. 6, 2018, 9:2873, 11 pages.
[cited by applicant]
Song et al., “Chimeric NKG2D CAR-Expressing T Cell-Mediated Attack of Human Ovarian Cancer Is Enhanced by Histone Deacetylase Inhibition,” Hum. Gene Ther., Mar. 2013, 24(3):295-305.
[cited by applicant]
Song et al., “In Vivo Persistence, Tumor Localization, and Antitumor Activity of CAR-Engineered T Cells Is Enhanced by Costimulatory Signaling through CD137 (4-1BB),” Cancer Res., Jul. 2011, 71(13):4617-4627.
[cited by applicant]
Srpan et al., “Shedding of CD16 disassembles the NK cell immune synapse and boosts serial engagement of target cells,” J. Cell. Biol., Sep. 2018, 217(9):3267-3283.
[cited by applicant]
Stawikowska et al., “Activity of ADAM17 (a disintegrin and metalloprotease 17) is regulated by its noncatalytic domains and secondary structure of its substrates,” J. Biol. Chem., Aug. 2, 2013, 288:22871-22879.
[cited by applicant]
Strauss-Albee et al., “Coordinated regulation of natural killer receptor expression in the maturing human immune system,” J. Immunol., Nov. 2014, 193(10):4871-4879.
[cited by applicant]
Strauss-Albee et al., “Human NK cell repertoire diversity reflects immune experience and correlates with viral susceptibility,” Sci. Transl. Med., Jul. 2015, 7(297):297ra115.
[cited by applicant]
Tatusova et al., “BLAST 2 Sequences, a new tool for comparing protein and nucleotide sequences,” FEMS Microbiol. Letters, May 15, 1999, 174:247-250.
[cited by applicant]
Teachey et al., “Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia,” Canc. Disc., Jun. 2016, 6(6):664-679.
[cited by applicant]
Teillaud et al., “Natural and recombinant soluble low-affinity Fe γ R: detection, purification, and functional activities,” Immunomethods., Feb. 1994, 4(1):48-64.
[cited by applicant]
Teillaud et al., “Soluble CD16 binds peripheral blood mononuclear cells and inhibits pokeweed-mitogen-induced responses,” Blood, Nov. 15, 1993, 82(10):3081-3090.
[cited by applicant]
Themeli et al., “Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy,” Nature Biotechnol, Oct. 2013, 31(10):928-933.
[cited by applicant]
Themeli et al., “New Cell Sources for T Cell Engineering and Adoptive Immunotherapy,” Cell Stem Cell, Apr. 2, 2015, 16(4):357-366.
[cited by applicant]
Thorp et al., “Shedding of the Mer tyrosine kinase receptor is mediated by ADAM17 protein through a pathway involving reactive oxygen species, protein kinase Cdelta, and p38 mitogen-activated protein kinase (MAPK),” J B…
[cited by applicant]
Tian et al., “Bioluminescent imaging demonstrates that transplanted human embryonic stem cell-derived CD34(+) cells preferentially develop into endothelial cells,” Stem Cells, 2009, 27:2675-2685.
[cited by applicant]
Tokuriki et al. Stability effects of mutations and protein evolvability. Curr Opin Structural Biol 19: 596-604, 2009.
[cited by applicant]
Topfer et al., “DAP12-Based Activating Chimeric Antigen Receptor for NK Cell Tumor Immunotherapy,” J Immunol., Apr. 1, 2015, 194(7):3201-3212.
[cited by applicant]
Tosi et al., “Surface expression of Fcγ receptor III (CD16) on chemoattractant-stimulated neutrophils is determined by both surface shedding and translocation from intracellular storage compartments,” J. Clin. Invest., …
[cited by applicant]
Tucher et al., “LC-MS based cleavage site profiling of the proteases ADAM10 and ADAM17 using proteome-derived peptide libraries,” J. Proteome Res., 2014, 13:2205-2214.
[cited by applicant]
Vanherberghen et al., “Classification of human natural killer cells based on migration behavior and cytotoxic response,” Blood, Feb. 2013, 121(8):1326-1334.
[cited by applicant]
Veeramani et al., “Rituximab infusion induces NK activation in lymphoma patients with the high-affinity CD16 polymorphism,” Blood, Sep. 2011, 118(12):3347-3349.
[cited by applicant]
Vivier et al., “Natural Killer Cell Signaling Pathways,” Science., Nov. 26, 2004, 306(5701):1517-1519.
[cited by applicant]
Vogelpoel et al. Control of cytokine production by human Fc gamma receptors: implications for pathogen defense and autoimmunity. Front Immunol 6: 79, 2015.
[cited by applicant]
Walcheck et al., “ADAM-17-independent shedding of L-selectin,” J. Leukoc. Biol., 2003, 74:389-394.
[cited by applicant]
Walcheck et al., “iNK-CD64/16A cells: a promising approach for ADCC”, Expert Opinion on Biological Therapy, Sep. 2019, 19(12):1229-1232.
[cited by applicant]
Wang et al., “ADAM17 cleaves CD16b (FcyRlllb) in human neutrophils,” Biochim. Biophys. Acta., Mar. 2013, 1833(3):680-685.
[cited by applicant]
Wang et al., “Different signaling pathways stimulate a disintegrin and metalloprotease-17 (ADAMI 7) in neutrophils during apoptosis and activation,” J. Biol. Chem., 2011, 286:38980-38988.
[cited by applicant]
Wang et al., “Natural killer cell-produced IFN-γ and TNF-α induce target cell cytolysis through up-regulation of ICAM-1,” J. Leukoc. Biol., Feb. 2012, 91(2):299-309.
[cited by applicant]
Wang et al., “NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy,” Front. Immunology, Jul. 27, 2015, 6:368, 15 pages.
[cited by applicant]
Wang et al., “Regulation of mature ADAM17 by redox agents for L-selectin shedding,” J. Immunol., Feb. 15, 2009, 182(4):2449-2457.
[cited by applicant]
Warburton et al., “Treatment of HER-2/neu overexpressing breast cancer xenograft models with trastuzumab (Herceptin) and gefitinib (ZD1839): drug combination effects on tumor growth, HER-2/neu and epidermal growth facto…
[cited by applicant]
Wells, J.A. Additivity of mutational effects in proteins. Biochemistry 29(37): 8509-8517, 1990.
[cited by applicant]
Wiemik et al., “Targeting natural killer cells to acute myeloid leukemia in vitro with a CD16 x 33 bispecific killer cell engager and ADAM17 inhibition,” Clin. Canc. Res., Jul. 2013, 19(14): 3844-3855.
[cited by applicant]
Wikipedia.org [online], “Chimeric antigen receptor T cell” retrieved on Jul. 16, 2019, retrieved from URL<https://en.wikipedia.org/wiki/Chimeric_antigen_receptor_T_cell>, 13 pages.
[cited by applicant]
Wilber et al., “Efficient and stable transgene expression in human embryonic stem cells using transposon-mediated gene transfer,” Stem Cells, Nov. 2007, 25(11):2919-2927.
[cited by applicant]
Wilken et al., “Trastuzumab Sensitizes Ovarian Cancer Cells to EGFR-targeted Therapeutics,” J. Ovarian Res., 2010, 3:7, 9 pages.
[cited by applicant]
Wolan et al., “Crystal structure of the murine NK cell-activating receptor NKG2D at 1.95 A” Nat. Immunology, Mar. 2001, 2(3):248-254.
[cited by applicant]
Woll et al., “Human Embryonic Stem Cell-Derived NK Cells Acquire Functional Receptors and Cytolytic Activity,” J Immunol., Oct. 15, 2005, 175(8):5095-5103.
[cited by applicant]
Woll et al., “Human embryonic stem cells differentiate into a homogeneous population of natural killer cells with potent in vivo antitumor activity,” Blood, Jun. 11, 2009, 113(24):6094-6101.
[cited by applicant]
Wu et al., “A novel polymorphism of FcγRIIIa (CD16) alters receptor function and predisposes to autoimmune disease,” J. Clin. Invest., Sep. 1997, 100(5):1059-1070.
[cited by applicant]
Wu et al., “DNAM-1-based chimeric antigen receptors enhance T cell effector function and exhibit in vivo efficacy against melanoma,” Cancer Immunology, Immunotherapy, Apr. 2015, 64(4):409-418.
[cited by applicant]
Xie et al., “Seamless gene correction of β-thalassemia mutations in patient-specific iPSCs using CRISPR/Cas9 and piggyBac,” Genome Res., 2014, 24:1526-1533.
[cited by applicant]
Yahata et al., “cHS4 Insulator-mediated Alleviation of Promoter Interference during Cell-based Expression of Tandemly Associated Transgenes,” J. Mol. Biol., Nov. 30, 2007, 374(3):580-590.
[cited by applicant]
Yang et al., “Phase I Study of Random Healthy Donor-Derived Allogeneic Natural Killer Cell Therapy in Patients with Malignant Lymphoma or Advanced Solid Tumors,” Canc. Immunol. Res., Mar. 2016, 4(3):215-224.
[cited by applicant]
Zeng et al., “Generation of ‘Off-the-Shelf’ Natural Killer Cells from Peripheral Blood Cell-Derived Induced Pluripotent Stem Cells,” Stem Cell Reports, Dec. 2017, 9(6):1796-1812.
[cited by applicant]
Zhang et al., “Cancer Immunotherapy Using a Bispecific NK Receptor Fusion Protein that Engages both T Cells and Tumor Cells,” Canc. Res., Mar. 2011, 71(6):2066-2076.
[cited by applicant]
Zhang et al., “Chimeric Antigen Receptor-Engineered NK-92 Cells: An Off-the-Shelf Cellular Therapeutic for Targeted Elimination of Cancer Cells and Induction of Protective Antitumor Immunity,” Front. Immunol., May 2017,…
[cited by applicant]
Zhang et al., “Generation of antitumor responses by genetic modification of primary human T cells with a chimeric NKG2D receptor,” Cancer Research, Jun. 2006, 66(11):5927-5933.
[cited by applicant]